Last reviewed · How we verify
DL-3-n-butylphthalide
At a glance
| Generic name | DL-3-n-butylphthalide |
|---|---|
| Also known as | CSPC NBP Pharmaceutical Co., Ltd., Shijiazhuang, China, NBP |
| Sponsor | First Hospital of China Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy (PHASE4)
- Effects of DL-3-n-butylphthalide on Chemotherapy-Induced Cognitive Impairment (PHASE4)
- Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER) (PHASE3)
- Efficacy of Butylphthalide on Symptomatic Atherosclerotic Stenosis in Middle Cerebral Artery (NA)
- Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke (PHASE1, PHASE2)
- DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil
- NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events (PHASE3)
- A Clinical Study on the Treatment of Cerebral Small Vascular Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |